{
    "_id" : ObjectId("5ac0c6c618dd7f182c8fc382"),
    "topline" : "Albert Bourla Elected to Pfizer’s Board of Directors",
    "short_desc" : "- Albert Bourla Elected to Pfizer’s Board of Directors\n\nPfizer Inc. today announced the election of Albert Bourla, DVM, Ph.D. to its Board of Directors, effective immediately.\nDr. Bourla, age 56, is currently the Chief Operating Officer (COO) of Pfizer.",
    "url" : "https://www.pfizer.com/news//news/press-release/press-release-detail/albert_bourla_elected_to_pfizer_s_board_of_directors"
}
{
    "_id" : ObjectId("5ac0c6c618dd7f182c8fc383"),
    "topline" : "Pfizer Announces Update on European Marketing Authorization Application for SUTENT® (sunitinib) in Adult Patients at High Risk of Recurrent Renal Cell Carcinoma",
    "short_desc" : "- Pfizer Announces Update on European Marketing Authorization Application for SUTENT® (sunitinib) in Adult Patients at High Risk of Recurrent Renal Cell Carcinoma\n\nPfizer Inc. (NYSE:PFE) today announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has recommended against expanding use of SUTENT® (sunitinib) to include the adjuvant treatment of adult patients at a high risk of recurrent renal cell carcinoma (RCC) following nephrectomy (surgical removal of the cancerous kidney).",
    "url" : "https://www.pfizer.com/news//news/press-release/press-release-detail/pfizer_announces_update_on_european_marketing_authorization_application_for_sutent_sunitinib_in_adult_patients_at_high_risk_of_recurrent_renal_cell_carcinoma"
}
{
    "_id" : ObjectId("5ac0c6c618dd7f182c8fc384"),
    "topline" : "Pfizer Receives Positive CHMP Opinion for Two Hematology Medicines, MYLOTARG™ and BOSULIF®",
    "short_desc" : "- Pfizer Receives Positive CHMP Opinion for Two Hematology Medicines, MYLOTARG™ and BOSULIF®\n\nPfizer Inc. (NYSE:PFE) today announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has adopted positive opinions recommending that two Pfizer hematology medicines be granted marketing authorizations in the European Union (EU).",
    "url" : "https://www.pfizer.com/news//news/press-release/press-release-detail/pfizer_receives_positive_chmp_opinion_for_two_hematology_medicines_mylotarg_and_bosulif"
}
{
    "_id" : ObjectId("5ac0c6c618dd7f182c8fc385"),
    "topline" : "Dan R. Littman Elected to Pfizer’s Board of Directors",
    "short_desc" : "- Dan R. Littman Elected to Pfizer’s Board of Directors\n\nPfizer Inc. today announced the election of Dr. Dan R. Littman to its Board of Directors. Dr. Littman, age 65, was also appointed to the Corporate Governance and Science and Technology Committees of Pfizer’s Board.",
    "url" : "https://www.pfizer.com/news//news/press-release/press-release-detail/dan_r_littman_elected_to_pfizer_s_board_of_directors"
}
{
    "_id" : ObjectId("5ac0c6c618dd7f182c8fc386"),
    "topline" : "Pfizer Invites Public to View and Listen to Webcast of Pfizer Presentation at Healthcare Conference",
    "short_desc" : "- Pfizer Invites Public to View and Listen to Webcast of Pfizer Presentation at Healthcare Conference\n\nPfizer invites investors and the general public to view and listen to a webcast of a presentation by Andy Schmeltz, Global President, Oncology, and Chris Boshoff, Senior Vice President and Head, Immuno-Oncology, Early Development and Translational Oncology, at the Cowen and Company 38th Annual Healthcare Conference",
    "url" : "https://www.pfizer.com/news//news/press-release/press-release-detail/pfizer_invites_public_to_view_and_listen_to_webcast_of_pfizer_presentation_at_healthcare_conference-22"
}
{
    "_id" : ObjectId("5ac0c6c618dd7f182c8fc387"),
    "topline" : "Pfizer Announces Favorable Outcome of FDA Advisory Committee Meeting on XELJANZ® (tofacitinib) for Moderately to Severely Active Ulcerative Colitis",
    "short_desc" : "-  Pfizer Announces Favorable Outcome of FDA Advisory Committee Meeting on XELJANZ® (tofacitinib) for Moderately to Severely Active Ulcerative Colitis\n\nNEW YORK, N.Y., March 8, 2018 – Pfizer Inc. announced a positive outcome from today’s U.S. Food and Drug Administration (FDA) Gastrointestinal Drugs Advisory Committee (GIDAC) meeting. The GIDAC met to discuss Pfizer’s supplemental New Drug Application (sNDA) for XELJANZ® (tofacitinib), which is currently under review by the FDA, for the treatment of adult patients with moderately to severely active ulcerative colitis (UC).",
    "url" : "https://www.pfizer.com/news//news/press-release/press-release-detail/pfizer_announces_favorable_outcome_of_fda_advisory_committee_meeting_on_xeljanz_tofacitinib_for_moderately_to_severely_active_ulcerative_colitis"
}
{
    "_id" : ObjectId("5ac0c6c618dd7f182c8fc388"),
    "topline" : "Findings Released from Largest Real-World Data Analysis of Non-Valvular Atrial Fibrillation Patients Receiving Direct Oral Anticoagulants",
    "short_desc" : "- Findings Released from Largest Real-World Data Analysis of Non-Valvular Atrial Fibrillation Patients Receiving Direct Oral Anticoagulants\n\nBristol-Myers Squibb Company (NYSE: BMY) and Pfizer Inc. (NYSE: PFE) will present findings today from a real-world data (RWD) analysis titled, Comparison of Effectiveness, Safety, and the Net Clinical Outcome between Different Direct Oral Anticoagulants in 162,707 Non-Valvular Atrial Fibrillation Patients Treated in US Clinical Practice.",
    "url" : "https://www.pfizer.com/news//news/press-release/press-release-detail/findings_released_from_largest_real_world_data_analysis_of_non_valvular_atrial_fibrillation_patients_receiving_direct_oral_anticoagulants"
}
{
    "_id" : ObjectId("5ac0c6c618dd7f182c8fc389"),
    "topline" : "U.S. FDA Grants Priority Review for a Supplemental New Drug Application (sNDA) for XTANDI® (enzalutamide) in Non-Metastatic Castration-Resistant Prostate Cancer (CRPC)",
    "short_desc" : "- U.S. FDA Grants Priority Review for a Supplemental New Drug Application (sNDA) for XTANDI® (enzalutamide) in Non-Metastatic Castration-Resistant Prostate Cancer (CRPC)\n\nPfizer Inc. (NYSE: PFE) and Astellas Pharma Inc. (TSE: 4503, President and CEO: Yoshihiko Hatanaka, “Astellas”) announced today that a supplemental New Drug Application (sNDA) for XTANDI® (enzalutamide) has been accepted for filing and granted Priority Review designation by the U.S. Food and Drug Administration...",
    "url" : "https://www.pfizer.com/news//news/press-release/press-release-detail/u_s_fda_grants_priority_review_for_a_supplemental_new_drug_application_snda_for_xtandi_enzalutamide_in_non_metastatic_castration_resistant_prostate_cancer_crpc"
}
{
    "_id" : ObjectId("5ac0c6c618dd7f182c8fc38a"),
    "topline" : "Pfizer Reports Top-Line Results from a Study of CHANTIX®/CHAMPIX® (varenicline) in Adolescent Smokers",
    "short_desc" : "- Pfizer Reports Top-Line Results from a Study of CHANTIX®/CHAMPIX® (varenicline) in Adolescent Smokers\n\nPfizer Inc. (NYSE:PFE) announced today results from a Phase 4 study evaluating the efficacy and safety of CHANTIX®/CHAMPIX® (varenicline) for smoking cessation in nicotine dependent adolescents 12-19 years of age. The study did not meet its primary endpoint of the four-week continuous abstinence rate at weeks 9 through 12 for CHANTIX/CHAMPIX compared to placebo. The study is a regulatory post marketing commitment for CHANTIX/CHAMPIX in the U.S. and EU for adolescents 12-16 years and 12-17 years of age, respectively.",
    "url" : "https://www.pfizer.com/news//news/press-release/press-release-detail/pfizer_reports_top_line_results_from_a_study_of_chantix_champix_varenicline_in_adolescent_smokers"
}
{
    "_id" : ObjectId("5ac0c6c618dd7f182c8fc38b"),
    "topline" : "Pfizer Announces Positive Topline Results From Phase 3 ATTR-ACT Study Of Tafamidis In Patients With Transthyretin Cardiomyopathy",
    "short_desc" : "- Pfizer Announces Positive Topline Results From Phase 3 ATTR-ACT Study Of Tafamidis In Patients With Transthyretin Cardiomyopathy\n\nPfizer Inc. announced today that the Tafamidis Phase 3 Transthyretin Cardiomyopathy (ATTR-ACT) study evaluating tafamidis for the treatment of transthyretin cardiomyopathy met its primary endpoint, demonstrating a statistically significant reduction in the combination of all-cause mortality and frequency of cardiovascular-related hospitalizations compared to placebo at 30 months.",
    "url" : "https://www.pfizer.com/news//news/press-release/press-release-detail/pfizer_announces_positive_topline_results_from_phase_3_attr_act_study_of_tafamidis_in_patients_with_transthyretin_cardiomyopathy"
}